CLINICAL_TRIALS
trial_result
· 2012-03-30
Clinical Trial Update: Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma [Phase 2]
Summary
Phase 2 trial of anti-angiogenesis agent AG-013736 in metastatic melanoma with results posted by Pfizer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Melanoma, Skin Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2012-03-30